A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis

Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis - A Multicenter Retrospective Analysis

This was a retrospective, multi-center observational study conducted across four allergy departments in Europe (Berlin, Leipzig, Barcelona, and Basel). The study included patients with immunoglobulin E (IgE)-mediated food allergy who were treated with omalizumab, either as monotherapy or in combination with oral immunotherapy (OIT) between 2002-2022.

Inclusion criteria:

• A confirmed history of food allergy, either with or without prior anaphylaxis.
• Treated with omalizumab, either as monotherapy or in combination with OIT.

Exclusion Criteria:

None identified.